Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US9920041B2 · kind B2 · utility

2Cited by

4References

12Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Hui Li · Santa Clara, US
Thilo J. Heckrodt · San Francisco, US
Yan Chen · Sunnyvale, US
Darren McMurtrie · Daly City, US
Vanessa Taylor · San Francisco, US
Rajinder Singh · Belmont, US
Pingyu Ding · Foster City, US
Rose Yen · San Francisco, US

Key dates

Filing date	Feb 22, 2017
Grant date	Mar 20, 2018
Priority date	—
Expiry date	Feb 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/05
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.